Identification of a new HLA-A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma-associated antigen HCA587

摘要

For the development of peptide-based cancer immunotherapies, we aimed to identify specific HLA-A*0201-restricted CTL epitopes in hepatocellular carcinoma (HCC) associated antigen HCA587, which has been identified as a member of the cancer/testis (CT) antigens highly expressed in HCC. We first combined the use of an HLA-A*0201/peptide binding algorithm and T2 binding assays with the induction of specific CD8⁺ T cell lines from normal donors by in vitro priming with high-affinity peptides, then IFN-γ release and cytotoxicity assays were employed to identify the specific HLA-A*0201 CD8⁺ T cell epitope using peptide-loaded T2 cells or the HCA587 protein⁺ HCC cell line HepG2. In the six candidate synthesized peptides, two peptides showed higher binding ability in T2 binding assays. No. 2 peptide, encompassing amino acid residues FLAKLNNTV (HCA587317−325), was able to activate a HCA587-specific CD8⁺ T-cell response in human lymphocyte cultures from two normal donors and two HCC patients, and these HCA587-specific CD8⁺ T cells recognized peptide-pulsed T2 cells as well as the HCA587 protein⁺ HCC cell line HepG2 in IFN-γ release and cytotoxicity assays. The results indicate that no. 2 peptide is a new HLA-A*0201-restricted CTL epitope capable of inducing HCA587-specific CTLs. Our data suggest that identification of this new HCA587/HLA-A*0201 peptide FLAKLNNTV may facilitate the design of peptide-based immunotherapies for the treatment of HCA587-bearing HCC patients.